Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09ENR
|
|||
| Former ID |
DIB007945
|
|||
| Drug Name |
Itarnafloxin
|
|||
| Synonyms |
Quarfloxin; CX-3385; CX-3543; Quadruplex DNA oncogene inhibitor (cancer), Cylene; C-Myc/VEGF oncogene inhibitor (cancer), Cylene
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 2 | [1] | |
| Company |
Cylene Pharmaceuticals Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C35H33FN6O3
|
|||
| Canonical SMILES |
CN1CCCC1CCNC(=O)C2=CN3C4=CC5=CC=CC=C5C=C4OC6=C3C(=CC(=C6N7CCC(C7)C8=NC=CN=C8)F)C2=O
|
|||
| InChI |
1S/C35H33FN6O3/c1-40-13-4-7-24(40)8-10-39-35(44)26-20-42-29-15-21-5-2-3-6-22(21)16-30(29)45-34-31(42)25(33(26)43)17-27(36)32(34)41-14-9-23(19-41)28-18-37-11-12-38-28/h2-3,5-6,11-12,15-18,20,23-24H,4,7-10,13-14,19H2,1H3,(H,39,44)/t23?,24-/m0/s1
|
|||
| InChIKey |
WOQIDNWTQOYDLF-CGAIIQECSA-N
|
|||
| CAS Number |
CAS 865311-47-3
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Nucleolin (NCL) | Target Info | Inhibitor | [1] |
| NetPath Pathway | TCR Signaling Pathway | |||
| IL2 Signaling Pathway | ||||
| Pathway Interaction Database | Aurora B signaling | |||
| Validated targets of C-MYC transcriptional activation | ||||
| Regulation of Telomerase | ||||
| Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling | ||||
| WikiPathways | Pathogenic Escherichia coli infection | |||
| miR-targeted genes in squamous cell - TarBase | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Targeting G-quadruplexes in gene promoters: a novel anticancer strategy . Nat Rev Drug Discov. 2011 April; 10(4): 261-275. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.